Affiliation:
1. Russian Medical Academy of Continuous Professional Education
Abstract
Modern approaches to interpreting the results of randomized trials, which can reduce the distortion of information when they are presented to a wide range of doctors, are discussed in the article. Data on the role of taking into account multiple comparisons in the planning and analysis of large randomized clinical trials are given. The validity and approaches to using a hierarchical approach to assessing the statistical significance of indicators (“endpoints”) in cases where, in accordance with a pre-adopted study protocol, several indicators are supposed to be evaluated are considered in detail. Approaches to interpreting the p value as well as 95% confidence intervals are considered. Particular attention is paid to the interpretation of the components of the main combined indicator, since when interpreting just such data, the presentation of the results of the study and the manipulation of doctors' opinions may be distorted. This is especially true for data on mortality and mortality from complications of cardiovascular diseases. Modern approaches to the analysis of research results using methods other than the usual Kaplan-Meier analysis, in particular, the method based on the calculation of the "win ratio" are discussed. Data obtained in modern clinical studies are given as examples.
Publisher
Stolichnaya Izdatelskaya Kompaniyaizdat
Subject
Pharmacology (medical),Cardiology and Cardiovascular Medicine
Reference20 articles.
1. Laporte S, Diviné M, Girault D. Clinical research and methodology: What usage and what hierarchical order for secondary endpoints? Therapie. 2016;71(1):27-41. DOI:10.1016/j.therap.2016.01.002.
2. Committee for Medicinal Products for Human Use (CHMP). Points to consider on multiplicity issues in clinical trials — CPMP/EWP/908/99; 2002 [cited 2022 Jan 10]. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/points-consider-multiplicity-issuesclinical-trials_en.pdf.
3. Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28. DOI:10.1056/NEJMoa1504720.
4. Goldberg R, Gore JM, Barton B, Gurwitz J. Individual and composite study endpoints: separating the wheat from the chaff. Am J Med. 2014;127(5):379-84. DOI:10.1016/j.amjmed.2014.01.011.
5. Freemantle N, Calvert M, Wood J, et al. Composite outcomes in randomized trials: greater precision but with greater uncertainty? JAMA. 2003;289(19):2554-9. DOI:10.1001/jama.289.19.2554.